This concept ensures data analysis based on a comparable data input. Differences in preoperative diagnostics, completeness of histopathological evaluation and short-term outcomes for Germany, Poland and Italy might result from disparities in socioeconomic factors and DMXAA mouse implementation of existing guidelines. Further activities are necessary to warrant the use of common standards in outcome control.”
“Introduction: Acne belongs to the

most common skin diseases and has a prevalence in the adolescence of nearly 100% and in adults of about 4%. The quality of life indes is significantly reduced und has impact on daily activities and social life and physical and psychological well being as well. The socioeconomic relevance is based not only on its prevalence but on direct and indirect costs. For

acne therapy the knowledge on therapeutic costs is of importance but the cost benefit ratio as well.

Goal: Evidence of therapeutic costs in acne and economic benefit of the therapy.

Methods: Systematic beta-catenin phosphorylation review of Cochrane data.

Results: Calculations reveal general costs of acne treatment in Germany over 400 Mill. Euro per year. For the treatment with topical retinoids, BPO and antibiotics as well as systemic drugs only a few studies on costeffectiveness are available. For topical treatments results are not conclusive and dependent on the different health systems. New topical combinations may have a better economic outcome, however, more studies are needed. With regard to systemic therapies of moderate to severe acne based on the international

references the cost-benefit ratio favours the treatment with oral isotretinoin on the long-term outcome. Superiority is based on the relationship of costs and clinical outcome and the increased quality of life as well (cost-benefit ratio). It has to be emphazised that only longterm observations over years ML323 will lead to a valid calculation of costs and benefit.

Facit: Taking the high social and quality of life impact into consideration an early, well targeted and effective therapy is prevailing. Initial higher cost are balanced by a high quality of outcome under experienced dermatological supervision. The patients benefit is ranked over the final costs because of its medical, social and ethical aspects.

To sample more differentiated data on pharmacoeconomic aspects well designed new clinical studies are to be set up.”
“Tailored operative strategies have been proposed for patients with bilobar colorectal liver metastases (CLM). The aim of the study was to evaluate the long-term outcome, safety and efficacy, including cancer-specific survival, morbidity, and mortality, of three different surgical strategies for extensive bilateral CLM.

This is a retrospective study of a prospective database of 356 consecutive patients, who underwent hepatic resection due to CLM between January 2003 and January 2009.